Trials / Unknown
UnknownNCT01397838
Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women
Phase 1 Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- OsteoBuild Ltd. · Industry
- Sex
- Female
- Age
- 45 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Recent studies have shown that inhibition of Aquaporine-9 channels may ameliorate the bone degradation process. Pro-bone is an AQ - 9 channels inhibitor. This study is design to evaluate the safety of Pro-bone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pro-Bone | 500 mg Capsules of Pro-Bone twice daily |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2011-12-01
- Completion
- 2012-01-01
- First posted
- 2011-07-20
- Last updated
- 2011-07-20
Source: ClinicalTrials.gov record NCT01397838. Inclusion in this directory is not an endorsement.